Skip to main content

Main menu

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology

User menu

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • More
    • About Kidney360
    • Advertising
    • Disqus Commenting
    • Reprint Information
    • Feedback
    • Email Alerts
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow Kidney360 on Twitter
  • Community Forum
  • Kidney360 RSS
Original InvestigationsDialysis

SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19

Xiaoling Wang, Amrish Patel, Lela Tisdale, Zahin Haq, Xiaoling Ye, Rachel Lasky, Priscila Preciado, Xia Tao, Gabriela Ferreira Dias, Joshua E. Chao, Mohamad Hakim, Maggie Han, Ohnmar Thwin, Jochen Raimann, Dinesh Chatoth, Peter Kotanko and Nadja Grobe
Kidney360 January 2021, 2 (1) 86-89; DOI: https://doi.org/10.34067/KID.0006102020
Xiaoling Wang
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amrish Patel
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lela Tisdale
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zahin Haq
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoling Ye
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Lasky
2Fresenius Medical Care North America, Waltham, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priscila Preciado
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xia Tao
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela Ferreira Dias
1Renal Research Institute, New York, New York
3Pontifical Catholic University of Paraná, Curitiba, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua E. Chao
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamad Hakim
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maggie Han
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ohnmar Thwin
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jochen Raimann
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dinesh Chatoth
4Fresenius Kidney Care, Atlanta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Kotanko
1Renal Research Institute, New York, New York
5Icahn School of Medicine at Mount Sinai, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadja Grobe
1Renal Research Institute, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Visual Abstract

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

Background To date, it is unclear whether SARS-CoV-2 is present in spent dialysate from patients with COVID-19 on peritoneal dialysis (PD). Our aim was to assess the presence or absence of SARS-CoV-2 in spent dialysate from patients on chronic PD who had a confirmed diagnosis of COVID-19.

Methods Spent PD dialysate samples from patients on PD who were positive for COVID-19 were collected between March and August 2020. The multiplexed, real-time RT-PCR assay contained primer/probe sets specific to different SARS-CoV-2 genomic regions and to bacteriophage MS2 as an internal process control for nucleic acid extraction. Demographic and clinical data were obtained from patients’ electronic health records.

Results A total of 26 spent PD dialysate samples were collected from 11 patients from ten dialysis centers. Spent PD dialysate samples were collected, on average, 25±13 days (median, 20; range, 10–45) after the onset of symptoms. The temporal distance of PD effluent collection relative to the closest positive nasal-swab RT-PCR result was 15±11 days (median, 14; range, 1–41). All 26 PD effluent samples tested negative at three SARS-CoV-2 genomic regions.

Conclusions Our findings indicate the absence of SARS-CoV-2 in spent PD dialysate collected at ≥10 days after the onset of COVID-19 symptoms. We cannot rule out the presence of SARS-CoV-2 in spent PD dialysate in the early stage of COVID-19.

  • dialysis
  • chronic kidney disease
  • COVID-19
  • dialysis solutions
  • peritoneal dialysis
  • RT-PCR
  • SARS-CoV-2

Introduction

Currently, individuals suspected of coronavirus disease 2019 (COVID-19) are tested for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid, mainly in nasopharyngeal-swab, oropharyngeal-swab, nasopharyngeal-aspirate, and bronchoalveolar-lavage specimens. SARS-CoV-2 was also detected in the blood of patients positive for COVID-19 (1,2). Viremia of SARS-CoV-2 has been proposed as a predictor of a severe clinical course (3,4).

Patients with kidney disease who are treated with peritoneal dialysis (PD) are a high-risk, vulnerable population. Previously, several viruses have been detected in spent PD dialysate, including hepatitis C virus and HIV (5,6). Data on the presence or absence of SARS-CoV-2 in spent PD dialysate are scarce; to date, results from only five patients on chronic PD have been reported. SARS-CoV-2 was found to be absent in four patients (7,8) and present in one (9). Therefore, it is currently unclear whether SARS-CoV-2 is present in spent PD dialysate, causing uncertainty and concerns for patients and their caregivers. To address these concerns, we collected and tested serial PD dialysate samples from patients on PD with confirmed COVID-19 for the presence of SARS-CoV-2.

Materials and Methods

Patient Selection

Collection of spent peritoneal dialysate from patients on PD who were positive for SARS-CoV-2 was done as a part of a quality-improvement project. The quality-improvement project was approved by the respective clinic governing bodies after legal and compliance review. Patients on PD who were positive for SARS-CoV-2 were contacted by US Fresenius Medical Care North America (FMCNA) healthcare professionals, who assisted with collecting the spent dialysate. Spent peritoneal dialysate was collected from patients on PD with a confirmed, positive, nasopharyngeal-swab test for SARS-CoV-2 from March until August 2020. Up to five spent PD dialysate samples per patient were collected. Patients received collection kits with instructions to leave gel ice packs in the freezer until the samples were collected and ready for shipment. Demographic and clinical data were retrospectively obtained from the patients’ electronic health records. Verbal consent was obtained from all participants. The dialysate shipments to Renal Research Institute complied with all of the respective federal and state regulations. All samples were shipped overnight with ice packs.

RNA Extraction and Real-Time RT-PCR

RNA was extracted from 400 µl of spent PD dialysate and eluted in 50 µl of elution buffer, using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit (A42352; Thermo Fisher) on the KingFisher Flex Purification System (5400630; Thermo Fisher). MS2 Phage Control was added to each sample, before RNA extraction, as an indicator of successful RNA extraction. Additionally, RNA was extracted from 2 ml of spent PD dialysate using the Qiagen QIAamp Viral RNA Mini Kit (52906; Qiagen), according to the instructions in the manual. MS2 phage control was added before RNA extraction. Final RNA was eluted in 30 µl of elution buffer. The PCR reaction mix was prepared using the TaqPath RT-PCR COVID-19 Combo Kit (A47814; Thermo Fisher). This kit contains probes that anneal to three specific SARS-CoV-2 target sequences: N protein, S protein, and ORF1ab. Diluted TaqPath COVID-19 Control (50 copies per PCR reaction) was used as a positive control. We used 5 µl of purified RNA from each sample for RT-PCR reaction on the QuantStudio 6 Pro Real-Time PCR System (A43159; Thermo Fisher). For each run, we used the same settings in the RT-PCR program as those provided in the instructions for the TaqPath RT-PCR COVID-19 Combo Kit. We performed 40 cycles of PCR amplification to achieve maximum detectability.

Statistical Analyses

Continuous variables are presented as mean±SD (range). Categoric variables are expressed as counts.

Results

We collected a total of 26 spent PD dialysate samples from 11 patients on PD from ten US FMCNA dialysis centers. Demographic and clinical data are shown in Table 1. Patients contributed an average of 2.4±1.4 samples (range, 1–5). Spent PD dialysate samples were collected, on average, 25±13 days (range, 10–45) after the onset of symptoms. The temporal distance of PD effluent (PDE) collection relative to the closest positive nasopharyngeal-swab RT-PCR test was 15±11 days (median, 14; range, 1–41); the time difference between PDE collection and the onset of symptoms for all 26 samples was 36±17 days (range, 10–75) (Figure 1). All PDE samples tested negative for SARS-CoV-2 RNA after 40 cycles of RT-PCR amplification. Of note, in patients 1, 3, and 11, RT-PCR tests of PDE were negative, although these patients were still considered positive for SARS-CoV-2, as confirmed by repeated nasopharyngeal-swab RT-PCR tests. The limit of detection is ten genomic copy equivalents (GCE) per PCR reaction, or 250 GCE/ml in PDE before RNA extraction. To enhance the detectability of SARS-CoV-2 RNA in PDE, we purified and concentrated RNA 66 times using the Qiagen RNA purification kit. The SARS-CoV-2 RNA testing result remained negative after 40 cycles of RT-PCR amplification. The calculated limit of detection was 30 GCE/ml in PDE in this case.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

All PDE samples tested negative for SARS-CoV-2 RNA after 40 cycles of RT-PCR amplification. Day 0 indicates the onset of symptoms of coronavirus disease 2019. Triangles indicate nasopharyngeal-swab dates; squares indicate time points when peritoneal dialysis effluent (PDE) samples were received and processed. Red triangles indicate a positive nasopharyngeal-swab test result; blue triangles indicate negative nasopharyngeal-swab test results. Blue squares indicate negative PDE test results. NS, nasopharyngeal-swab; RT-PCR, real-time RT-PCR.

Discussion

Our results, determined on the basis of the largest cohort of patients with COVID-19 on chronic PD to date, indicate that SARS-CoV-2 was not present in the spent PD dialysate collected in our population ≥10 days after the onset of symptoms. In our patients, COVID-19 was diagnosed by RT-PCR of nasopharyngeal-swab samples. The findings corroborate previous results in four patients on chronic PD reported by other groups (7,8). To the best of our knowledge, the report by Vischini et al. (9) is the only one finding a positive SARS-CoV-2 test in spent PD dialysate from a patient on chronic PD. The patient was diagnosed with COVID-19 and hospitalized for 40 days. Her PDE tested positive for SARS-CoV-2 multiple times, even at the time of discharge. Because viral culture was absent, it is unknown if this finding indicates viable SARS-CoV-2 or mere RNA remnants. Alternatively, the patient may have had an unusually high viral load throughout the illness (10). However, that is not typical. A virologic assessment study, published in April 2020, demonstrated that pharyngeal virus shedding was very high during the first week of symptoms, peaking at 7.11×108 RNA copies per throat swab on day 4 (10). No live virus could be isolated from pharyngeal samples taken 8 days after the onset of symptoms, in spite of ongoing high viral load (10).

It is important to consider the timing of PD dialysate collection relative to the onset of symptoms. In our patients, the earliest PD dialysate collection was 10 days after the onset of symptoms (patient 4). Therefore, we cannot rule out the presence of SARS-CoV-2 in the early stage of the disease. Candellier et al. (7,11) collected spent PD dialysate from three patients at 0, 3, 4, and 7 days after hospital admission; none of the samples tested positive for SARS-CoV-2, despite high initial viral loads (cycle threshold <30). Sadioglu et al. (8) reported on two PDE samples collected from a patient on days 3 and 4 after the onset of symptoms, and both tested negative for SARS-CoV-2. Similar to the above findings in patients on chronic PD, El Shamy et al. (12) reported no SARS-CoV-2 present in the spent dialysate of ten patients, hospitalized with COVID-19, who had acute kidney injuries that were treated with acute PD.

Coccolini et al. (13) reported on a surgical patient with SARS-CoV-2 and intact kidney function who suffered from small bowel volvulus and underwent emergency surgery. Barberis et al. (14) also reported on a patient severely ill with COVID-19 who underwent surgery. In both cases, RT-PCR of intraoperatively collected peritoneal fluid tested positive for SARS-CoV-2. Considering the circumstances, contamination from blood or other body fluid could be one source of the positive signal.

Only a small fraction of patients that tested positive for SARS-CoV-2 are viremic, and those are typically patients with severe COVID-19 symptoms (1⇓⇓–4). With a size of 60–140 nm, SARS-CoV-2 could theoretically enter the peritoneal cavity via translocation from the blood (11,15). Therefore, it could be argued that patients on PD with severe COVID-19 are more likely to be viremic and, thus, have potentially contagious spent dialysate. Viremic blood samples are not necessarily contagious, however. For example, a recent medRxiv preprint reported a study of 20 blood samples containing SARS-CoV-2 RNA; in viral cultures, no viral replication was detected, suggesting these blood samples were not infectious (M. Andersson et al., unpublished observations). To definitively answer the question of contagiousness of spent peritoneal dialysate, longitudinal studies—which include repeated RT-PCR testing and viral cultures of spent peritoneal dialysate from symptom onset to recovery—are warranted.

Disclosures

J.E. Chao, G.F. Dias, N. Grobe, M. Hakim, M. Han, O. Thwin, Z. Haq, P. Kotanko, A. Patel, P. Preciado, J. Raimann, X. Tao, L. Tisdale, X. Wang, and X. Ye are employees of the Renal Research Institute, a wholly owned subsidiary of FMCNA. D. Chatoth and R. Lasky are employees of FMCNA. D. Chatoth and P. Kotanko hold stock in Fresenius Medical Care. All remaining authors have nothing to disclose.

Funding

None.

Acknowledgments

The authors would like to thank all patients involved in the project. We are grateful for the support provided by home-therapy managers and home dialysis clinics.

Author Contributions

J.E. Chao, G.F. Dias, N. Grobe, M. Hakim, Z. Haq, A. Patel, P. Preciado, and X. Wang were responsible for investigation; D. Chatoth, N. Grobe, P. Kotanko, J. Raimann, and X. Wang reviewed and edited the manuscript; D. Chatoth, P. Kotanko, A. Patel, O. Thwin, and L. Tisdale were responsible for resources; N. Grobe, P. Kotanko, and X. Tao provided supervision; N. Grobe, P. Kotanko, X. Tao, and X. Wang conceptualized the study; N. Grobe, A. Patel, and X. Wang wrote the original draft; M. Han, A. Patel, P. Preciado, X. Tao, O. Thwin, and L. Tisdale were responsible for project administration; R. Lasky and J. Raimann were responsible for data curation; X. Wang was responsible for methodology; X. Wang and X. Ye were responsible for formal analysis; and all authors provided critical feedback and helped shape the research, analysis, and manuscript.

  • Received October 13, 2020.
  • Accepted December 1, 2020.
  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. Wang W,
    2. Xu Y,
    3. Gao R,
    4. Lu R,
    5. Han K,
    6. Wu G,
    7. Tan W
    : Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 323: 1843–1844, 2020 https://doi.org/10.1001/jama.2020.3786
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhang W,
    2. Du RH,
    3. Li B,
    4. Zheng XS,
    5. Yang XL,
    6. Hu B,
    7. Wang YY,
    8. Xiao GF,
    9. Yan B,
    10. Shi ZL,
    11. Zhou P
    : Molecular and serological investigation of 2019-nCoV infected patients: Implication of multiple shedding routes. Emerg Microbes Infect 9: 386–389, 2020 https://doi.org/10.1080/22221751.2020.1729071
    OpenUrl
  3. ↵
    1. Chen X,
    2. Zhao B,
    3. Qu Y,
    4. Chen Y,
    5. Xiong J,
    6. Feng Y,
    7. Men D,
    8. Huang Q,
    9. Liu Y,
    10. Yang B,
    11. Ding J,
    12. Li F
    : Detectable serum severe acute respiratory syndrome-coronavirus 2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus 2019. Clin Infect Dis 71: 1937–1942, 2020
    OpenUrlPubMed
  4. ↵
    1. Hagman K,
    2. Hedenstierna M,
    3. Gille-Johnson P,
    4. Hammas B,
    5. Grabbe M,
    6. Dillner J,
    7. Ursing J
    : SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: A retrospective cohort study [published online ahead of print August 28, 2020]. Clin Infect Dis
  5. ↵
    1. Farzadegan H,
    2. Ford D,
    3. Malan M,
    4. Masters B,
    5. Scheel PJ Jr.
    : HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int 50: 1659–1662, 1996 https://doi.org/10.1038/ki.1996.482
    OpenUrlCrossRefPubMed
  6. ↵
    1. Garcia EG,
    2. Del Peso G,
    3. Celadilla O,
    4. Castro MJ,
    5. Martinez V,
    6. Muñoz I,
    7. Sanchez-Villanueva R,
    8. de Guevara CL,
    9. Selgas R,
    10. Bajo MA
    : Efficacy of sodium hypochlorite in eradicating hepatitis C virus (HCV)-RNA from the peritoneal effluent of PD patients. Perit Dial Int 30: 644–646, 2010 https://doi.org/10.3747/pdi.2009.00137
    OpenUrlFREE Full Text
  7. ↵
    1. Candellier A,
    2. Scohy A,
    3. Gillet N,
    4. Muylkens B,
    5. Morelle J,
    6. Belkhir L,
    7. Coupeau D,
    8. Jadoul M,
    9. Goffin É
    : Absence of SARS-CoV-2 in the effluent of peritoneal dialysis patients. Perit Dial Int 40: 499–503, 2020 https://doi.org/10.1177/0896860820953061
    OpenUrl
  8. ↵
    1. Sadioglu RE,
    2. Aktar M,
    3. Gulten E,
    4. Eyupoglu S,
    5. Karahan ZC,
    6. Azap A,
    7. Sengul S,
    8. Ates K,
    9. Kutlay S
    : Does SARS-CoV-2 reach peritoneal effluent? Perit Dial Int 40: 520–521, 2020 10.1177/0896860820947331
    OpenUrl
  9. ↵
    1. Vischini G,
    2. D’Alonzo S,
    3. Grandaliano G,
    4. D’Ascenzo FM
    : SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis. Kidney Int 98: 237–238, 2020 https://doi.org/10.1016/j.kint.2020.05.005
    OpenUrl
  10. ↵
    1. Wölfel R,
    2. Corman VM,
    3. Guggemos W,
    4. Seilmaier M,
    5. Zange S,
    6. Müller MA,
    7. Niemeyer D,
    8. Jones TC,
    9. Vollmar P,
    10. Rothe C,
    11. Hoelscher M,
    12. Bleicker T,
    13. Brünink S,
    14. Schneider J,
    15. Ehmann R,
    16. Zwirglmaier K,
    17. Drosten C,
    18. Wendtner C
    : Virological assessment of hospitalized patients with COVID-2019. Nature 581: 465–469, 2020 https://doi.org/10.1038/s41586-020-2196-x
    OpenUrlCrossRefPubMed
  11. ↵
    1. Candellier A,
    2. Goffin É
    : Letter regarding “SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis”. Kidney Int 98: 512, 2020 https://doi.org/10.1016/j.kint.2020.05.034
    OpenUrl
  12. ↵
    1. El Shamy O,
    2. Vassalotti JA,
    3. Sharma S,
    4. Aydillo-Gomez T,
    5. Marjanovic N,
    6. Ramos I,
    7. García-Sastre A,
    8. Uribarri J
    : Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. Kidney Int 98: 782, 2020 https://doi.org/10.1016/j.kint.2020.06.012
    OpenUrl
  13. ↵
    1. Coccolini F,
    2. Tartaglia D,
    3. Puglisi A,
    4. Giordano C,
    5. Pistello M,
    6. Lodato M,
    7. Chiarugi M
    : SARS-CoV-2 is present in peritoneal fluid in COVID-19 patients. Ann Surg 272: e240–e242, 2020 https://doi.org/10.1097/SLA.0000000000004030
    OpenUrl
  14. ↵
    1. Barberis A,
    2. Rutigliani M,
    3. Belli F,
    4. Ciferri E,
    5. Mori M,
    6. Filauro M
    : Author response to: Comment on: SARS-Cov-2 in peritoneal fluid: An important finding in the Covid-19 pandemic. Br J Surg 107: e668, 2020
    OpenUrl
  15. ↵
    1. Zhu N,
    2. Zhang D,
    3. Wang W,
    4. Li X,
    5. Yang B,
    6. Song J,
    7. Zhao X,
    8. Huang B,
    9. Shi W,
    10. Lu R,
    11. Niu P,
    12. Zhan F,
    13. Ma X,
    14. Wang D,
    15. Xu W,
    16. Wu G,
    17. Gao GF,
    18. Tan W
    ; China Novel Coronavirus Investigating and Research Team: A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382: 727–733, 2020 https://doi.org/10.1056/NEJMoa2001017
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Kidney360: 2 (1)
Kidney360
Vol. 2, Issue 1
28 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19
Xiaoling Wang, Amrish Patel, Lela Tisdale, Zahin Haq, Xiaoling Ye, Rachel Lasky, Priscila Preciado, Xia Tao, Gabriela Ferreira Dias, Joshua E. Chao, Mohamad Hakim, Maggie Han, Ohnmar Thwin, Jochen Raimann, Dinesh Chatoth, Peter Kotanko, Nadja Grobe
Kidney360 Jan 2021, 2 (1) 86-89; DOI: 10.34067/KID.0006102020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
SARS-CoV-2 in Spent Dialysate from Chronic Peritoneal Dialysis Patients with COVID-19
Xiaoling Wang, Amrish Patel, Lela Tisdale, Zahin Haq, Xiaoling Ye, Rachel Lasky, Priscila Preciado, Xia Tao, Gabriela Ferreira Dias, Joshua E. Chao, Mohamad Hakim, Maggie Han, Ohnmar Thwin, Jochen Raimann, Dinesh Chatoth, Peter Kotanko, Nadja Grobe
Kidney360 Jan 2021, 2 (1) 86-89; DOI: 10.34067/KID.0006102020
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Funding
    • Acknowledgments
    • Author Contributions
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Investigations

  • Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease
  • Identification of Novel Biomarkers and Pathways for Coronary Artery Calcification in Nondiabetic Patients on Hemodialysis Using Metabolomic Profiling
  • Multidisciplinary Team versus a “Phosphate-Counting” App for Serum Phosphate Control: A Randomized Controlled Trial
Show more Original Investigations

Dialysis

  • COVID-19 Antibodies and Outcomes among Outpatient Maintenance Hemodialysis Patients
  • Inhibition of Lysyl Oxidase with β-aminopropionitrile Improves Venous Adaptation after Arteriovenous Fistula Creation
  • Factors Associated with Dialysis Discontinuation Outside of the Acute Care Setting
Show more Dialysis

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • Google Scholar

Keywords

  • dialysis
  • chronic kidney disease
  • COVID-19
  • dialysis solutions
  • peritoneal dialysis
  • RT-PCR
  • SARS-CoV-2

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • Kidney360
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About Kidney360
  • Kidney360 Email Alerts
  • Kidney360 Podcasts
  • Kidney360 RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Disqus Code of Conduct
  • Disqus Information
  • Feedback
  • Follow on Twitter
  • Subscribe to JASN and CJASN

© 2021 American Society of Nephrology

Online ISSN - 2641-7650

Powered by HighWire